-Reuter
FDA Advisory Panels Gives Thumbs Down To BrainStorm’s Lead Therapy
The FDA's Cellular, Tissue and Gene Therapies Advisory Committee meeting reviewing BrainStorm Cell Therapeutics Inc's (NASDAQ: BCLI) NurOwn application voted that NurOwn did not demonstrate substantial evidence of effectiveness for treatment of
